Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment
The Genetics of "Non-Response" in Adult AML
RATIONALE: Studying samples of bone marrow and blood from patients with cancer who failed treatment may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer resistance. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies biomarkers in samples from adult patients with acute myeloid leukemia who failed standard-of-care treatment.
研究概览
详细说明
OBJECTIVES:
- Define a "non-response" signature that will help up-front identification of cases of intermediate-risk acute myeloid leukemia (AML) destined to fail existing standard-of-care therapy.
- Identify biological pathways in the "non-response" group that can provide targets for novel therapeutics.
OUTLINE: DNA and RNA extracted from cryopreserved bone marrow cells and/or blood cells are analyzed for mutations and gene expression signatures (genome-wide methylation, mRNA and miRNA expression, and single nucleotide polymorphism (SNP) analysis) by microarray assays.
研究类型
注册 (预期的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Samples from previously untreated non-M3 acute myeloid leukemia (AML)
- Normal karyotype (NK) intermediate-risk disease
- Two or more vials of cryopreserved pretreatment bone marrow cells and/or two or more vials of cryopreserved pretreatment blood cells available from the Intergroup AML Repository
- Blast count ≥ 60%
- Eligible and evaluable for the patient's clinical trial, and did not have fatal induction toxicity
Response to protocol induction chemotherapy:
- Non-response: AML with failure to achieve a complete remission (CR) after induction chemotherapy ("7 & 3"-based therapy using cytatabine and/or daunorobicin hydrochloride (DNR) OR idarubicin and/or DNR
- Responders: continued complete remission (CCR) > 2 years
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
学习计划
研究是如何设计的？
研究衡量的是什么？
主要结果指标
结果测量 |
|---|
|
Genetic signature predictive of progression and drug resistance in AML
|
次要结果测量
结果测量 |
|---|
|
Identification of biological pathways in non-responder AML patients
|
合作者和调查者
调查人员
- 首席研究员：Jerry Radich, MD、Fred Hutchinson Cancer Center
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
- 具有 11q23 (MLL) 异常的成人急性髓性白血病
- 伴有 inv(16)(p13;q22) 的成人急性髓性白血病
- 成人急性髓性白血病伴 t(16;16)(p13;q22)
- 成人急性髓性白血病伴 t(8;21)(q22;q22)
- 未经治疗的成人急性髓性白血病
- 成人急性巨核细胞白血病 (M7)
- 成人急性低分化髓性白血病 (M0)
- 成人急性单核细胞白血病 (M5a)
- 成人急性单核细胞白血病 (M5b)
- 成熟型成人急性成髓细胞白血病 (M2)
- 未成熟的成人急性成髓细胞白血病 (M1)
- 成人急性粒单核细胞白血病 (M4)
- 成人急性嗜碱性白血病
- 成人急性嗜酸性粒细胞白血病
- 成人红白血病 (M6a)
- 成人纯红细胞白血病 (M6b)
- 伴有 del(5q) 的成人急性髓性白血病
其他研究编号
- FHCRC-9140
- CDR0000709269 (注册表标识符：PDQ (Physician Data Query))
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
白血病的临床试验
-
Shenzhen Second People's Hospital招聘中白血病 | 骨髓的 | 慢性的 | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | 积极的中国
基因表达分析的临床试验
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversity of Witwatersrand, South Africa; PD Hinduja Hospital and Medical Research Centre,... 和其他合作者完全的
-
Michigan State University招聘中
-
National Institute for Medical Research, TanzaniaUniversity of Kinshasa (UNIKIN), Congo, The Democratic Republic of the ( Prof Vivi Maketa); Research... 和其他合作者尚未招聘
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention完全的
-
Hvidovre University HospitalElsassFonden终止